SEARCH

SEARCH BY CITATION

References

  • 1
    Magee PJ, Rowland IR. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br. J. Nutr. April 2004; 91: 51331.
  • 2
    Flanigan RC, Shankey TV. The natural history of human prostate cancer. In: StevenA, LeibelMD, ScherHI, LangeP, RaghavanD (eds). Principles and Practice of Genitourinary Oncology. Lippincott-Raven Publishers, Philadelphia, 1997; 44350.
  • 3
    Isaacs JT. Molecular markers for prostate cancer metastasis. Am. J. Pathol. 1997; 150: 151121.
  • 4
    Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in site hybridization. Cancer Res. 1997; 57: 52431.
  • 5
    Cheng L, Song SY, Pretlow TG. Evidence of independent origin of multiple tumors from patients with prostate cancer. J. Natl Cancer Inst. 1998; 90: 2337.
  • 6
    Qian J, Bostwick DG, Takahashi S et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res. 1995; 55: 540814.
  • 7
    Sato K, Qian J, Slezak JM et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl Cancer Inst. 1999; 91: 157480.
  • 8
    Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am. J. Pathol. 1998; 153: 1418.
  • 9
    Kaltz-Wittmer C, Klenk U, Glaessgen A et al. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab. Invest. 2000; 80: 145564.
  • 10
    Reiter RE, Sato I, Thomas G. Coamplification of prostate stem cell antigen (PSCA) and myc in locally advanced prostate cancer. Genes Chromosomes Cancer 2000; 27: 95103.
  • 11
    Alers JC, Krijtenburg PJ, Rosenberg C. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab. Invest. 1997; 77: 43748.
  • 12
    Miyoshi Y, Uemura H, Fujinami K et al. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 2000; 43: 22532.
  • 13
    Qian J, Jenkins RB, Bostwick DG. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod. Pathol. 1997; 10: 111319.
  • 14
    Qian J, Hirasawa K, Bostwick DG. Loss of p53 and c-myc overrepresentation in stage T2−3 N1−3 M0 prostate cancer are potential markers for cancer progression. Mod. Pathol. 2002; 15: 3544.
  • 15
    Tsuchiya N, Slezak JM, Lieber MM, Bergstralh EJ, Jenkins RB. Clinical significance of alterations of chromosome 8 detected by fluorescence in site hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer 2002; 34: 36371.
  • 16
    International Union Against Cancer. TNM classification of malignant tumors. In: Sobin LH (ed.). Wiley-Liss Inc, New York, 1997; 1703.
  • 17
    Schwab M, Amler LC. Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer. Genes Chromosomes Cancer 1990; 1: 18193.
  • 18
    Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc. Natl Acad. Sci. USA 1986; 83: 29348.
  • 19
    Qian J, Bostwick DG, Takahashi S et al. Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Am. J. Pathol. 1996; 149: 11939.
  • 20
    DePinho RA, Schreiber-Agus N, Alt FW. Myc family oncogenes in the development of normal and neoplastic cells. Adv. Cancer Res. 1991; 57: 146.
  • 21
    Facchini LM, Penn LZ. The molecular role of myc in growth and transformation: discoveries lead to new insights. FASEB J. 1998; 12: 63351.
  • 22
    Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front. Biosci. 1998; 3: D25068.
  • 23
    Roger SK. An Atlas of Prostatic Disease, 2nd edn. The Parthenon Publishing Group, New York, 1999; 724.
  • 24
    Visakorpi T, Kallioniemi AH, Syvanen AC et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 1995; 55: 3427.
  • 25
    Van Den Berg C, Guan XY, Von Hoff D. DNA sequence amplification in human prostate cancer identified by chromosome microdissection. Clin. Cancer Res. 1995; 1: 1118.